Last reviewed · How we verify
NCT03584139
IRIS Hook Assisted Phacoemulsification in Vitrectomized Eyes
NA trial testing IRIS HOOK in Cataract in 62 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | Second Affiliated Hospital of Xi'an Jiaotong University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 1 April 2018 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- IRIS HOOK
- TRADITION
Conditions studied
- Cataract — all drugs for Cataract →
- Vitrectomy — all drugs for Vitrectomy →
Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Who can join
Adults 20 to 80, any sex, with Cataract or Vitrectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although phacoemulsification in previously vitrectomized eyes is a relatively safe procedure comparing with extracapsular cataract surgery, it is still more challenging than in eyes without previous vitrectomy because of the anatomical differences after PPV. Intraoperative difficulties such as abnormal anterior chamber deepening, unstable posterior capsules, and weakened zonules have been reported. The investigators aim to evaluate the efficacy and safety of a new simple iris hook assisted maneuver in phacoemulsification, then compare the incidence of intraoperative and postoperative complications of this technique with traditional phacoemulsification and phacoemulsification with 25-gauge vitreous irrigation. The latter two surgery methods are currently popular for cataract in vitrectomized eyes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and effectiveness of an iris hook assisted phacoemulsification in vitrectomized eyes.
Bai L, Wang YF, Tariq F, Zheng YP, et al · · 2021 · cited 1× · PMID 34804864 · DOI 10.18240/ijo.2021.11.13
Verify or expand the search:
- PubMed search for NCT03584139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other Second Affiliated Hospital of Xi'an Jiaotong University trials
Trials by the same sponsor.
- NCT07160361 — Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB · Phase 4 · not yet recruiting
- NCT07346456 — Comparison of IOL Formulas in Eyes With PCE≥15µm · completed
- NCT06998589 — Comparison of the Efficacy and Safety of Delicate Pulsed Light and Q-Switched 1064 nm Nd:YAG Laser in the Treatment of P · NA · completed
- NCT07305675 — Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment · NA · completed
- NCT06791005 — A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03584139 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Xi'an Jiaotong University
- Last refreshed: 6 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03584139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing